Emerging data from Huang X et al. [22] demonstrated that even dapagliflozin may ameliorate CI-AKI through suppression of HIF-1a/HE4/NF-kB signaling in vitro and in vivo, which is the pathway involved in hypoxia-induced injury. The gene discussed is NFKB1; the disease is acute kidney injury.